Gariani K, et al. - Given that some physicians avoid amoxicillin-clavulanate (AMC) for the oral therapy of diabetic foot infections (DFI), particularly for osteomyelitis (DFO), due to its poor bioavailability and bone penetration of all antibiotics from the β-lactam class, researchers conducted a retrospective cohort analysis in 794 DFI episodes, including 339 DFO cases. For a median of 20 days, oral AMC was prescribed. In patients with DFIs and DFOs, oral AMC is a reasonable option.